Kumatakenin alleviates LPS-induced acute lung injury by attenuating pulmonary oxidative stress and neutrophil extracellular trap formation through CMA-associated regulation of PRL2.
- DOI
- 10.1016/j.intimp.2026.117399
- Published
- 2026 Sep 9
- Container
- International immunopharmacology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.intimp.2026.117399,
title = {Kumatakenin alleviates LPS-induced acute lung injury by attenuating pulmonary oxidative stress and neutrophil extracellular trap formation through CMA-associated regulation of PRL2.},
author = {Hai D and Zhu X and Ye S and Ma L and Liu Y and Wei W and Zhang M and Ma X and Niu Y and Peng X and Yu J and Liu N},
year = {2026},
journal = {International immunopharmacology},
doi = {10.1016/j.intimp.2026.117399},
url = {https://doi.org/10.1016/j.intimp.2026.117399}
}RIS
TY - JOUR TI - Kumatakenin alleviates LPS-induced acute lung injury by attenuating pulmonary oxidative stress and neutrophil extracellular trap formation through CMA-associated regulation of PRL2. AU - Hai D AU - Zhu X AU - Ye S AU - Ma L AU - Liu Y AU - Wei W AU - Zhang M AU - Ma X AU - Niu Y AU - Peng X AU - Yu J AU - Liu N PY - 2026 JO - International immunopharmacology DO - 10.1016/j.intimp.2026.117399 UR - https://doi.org/10.1016/j.intimp.2026.117399 ER -
APA
D, H., X, Z., S, Y., L, M., Y, L., W, W., M, Z., X, M., Y, N., X, P., J, Y., & N, L. (2026). Kumatakenin alleviates LPS-induced acute lung injury by attenuating pulmonary oxidative stress and neutrophil extracellular trap formation through CMA-associated regulation of PRL2.. International immunopharmacology. https://doi.org/10.1016/j.intimp.2026.117399
Source records
- pubmed · retrieved 2026-09-25T15:37:35.889Z